Alembic Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication of Audited Financial Results as on 31st March, 2026.

Exceptional ItemCompliance View source PDF

APLLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-3.6%1-day move

₹780.90

prior close

₹780.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-4.3-4.5-5.5-6.9-3.6-4.0-4.1-3.1-2.9-3.6-6.2-4.0+8.8—

Up moveDown movePending

AI summary

Alembic Pharmaceuticals has published its audited financial results for Q4 FY2026 and full year ended 31 March 2026. Consolidated total income for Q4 stood at ₹1,847.72 crore (up 4.4% YoY) and full year at ₹7,344.90 crore. Net profit after tax for Q4 was ₹202.70 crore (up 29.2% YoY) and full year at ₹674.77 crore. Standalone Q4 profit after tax surged to ₹243.07 crore compared to just ₹75.34 crore in Q4 FY25. EPS for Q4 improved to ₹10.31 from ₹7.98 in the same period last year. The company reported an exceptional item in Q4 that reduced pre-tax profit from ₹143.38 crore to ₹118.62 crore.

Likely market impact

Strong profit growth with Q4 PAT more than tripling on standalone basis signals operational efficiency improvement. Exceptional items in Q4 warrant monitoring but full-year earnings momentum appears positive for shareholders.